These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38109988)

  • 1. Intensity of and adherence to lipid-lowering therapy as predictors of goal attainment and major adverse cardiovascular events in primary prevention.
    Mazhar F; Hjemdahl P; Sjölander A; Kahan T; Jernberg T; Carrero JJ
    Am Heart J; 2024 Mar; 269():118-130. PubMed ID: 38109988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensity of and Adherence to Lipid-Lowering Therapy as Predictors of Major Adverse Cardiovascular Outcomes in Patients With Coronary Heart Disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Sjölander A; Carrero JJ
    J Am Heart Assoc; 2022 Jul; 11(14):e025813. PubMed ID: 35861825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-lowering treatment intensity, persistence, adherence and goal attainment in patients with coronary heart disease.
    Mazhar F; Hjemdahl P; Clase CM; Johnell K; Jernberg T; Carrero JJ
    Am Heart J; 2022 Sep; 251():78-90. PubMed ID: 35654163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lipid-lowering treatment intensity and adherence on cardiovascular outcomes in patients with a recent myocardial infarction: a Swedish register-based study.
    Svensson MK; Sorio Vilela F; Leósdóttir M; Banefelt J; Lindh M; Dun AR; Norhammar A; Villa G
    Ups J Med Sci; 2022; 127():. PubMed ID: 35722183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
    Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
    Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in low-density lipoprotein cholesterol goal achievement and changes in lipid-lowering therapy after incident atherosclerotic cardiovascular disease: Danish cohort study.
    Ersbøll AK; Kristensen MS; Nybo M; Hede SM; Mikkelsen KH; Gislason G; Lytken Larsen M; Green A
    PLoS One; 2023; 18(5):e0286376. PubMed ID: 37256879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of lipid-lowering therapy on lipid-related residual risk factors: a prospective study.
    Li Z; Gao Y; Lu Q; Yin Z; Zhang S; Zhang W; Sui Y; Xu Y; Li J; Dou K; Qian J; Qiu H; Wu N
    Lipids Health Dis; 2024 May; 23(1):134. PubMed ID: 38715079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study.
    van de Borne P; Peeters A; Janssens L; Leone A; Lemmens R; Verhaegen A; De Meulemeester M; Balthazar Y; Heijmans S; Calozet Y; Paquot N; Carlier S; Hemelsoet D; Bray S; Ray KK
    Acta Cardiol; 2024 Feb; 79(1):20-29. PubMed ID: 35442151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
    Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
    Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
    Tan NC; Goh CC; Goh SC; Koh YL; Koh KH
    J Clin Pharm Ther; 2016 Dec; 41(6):677-683. PubMed ID: 27641514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
    Morgan CL; Durand A; McCormack T; Hughes E; Berni TR; Lahoz R
    BMJ Open; 2023 Nov; 13(11):e064541. PubMed ID: 38030254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary use of lipid-lowering therapy for secondary prevention in Korean patients with atherosclerotic cardiovascular diseases.
    Choi SY; Yang BR; Kang HJ; Park KS; Kim HS
    Korean J Intern Med; 2020 May; 35(3):593-604. PubMed ID: 31752475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of Patients With Atherosclerotic Cardiovascular Disease in Belgium and Current Treatment Patterns for the Management of Elevated LDL-C Levels.
    Maury E; Brouyère S; Jansen M
    Clin Cardiol; 2024 Sep; 47(9):e24330. PubMed ID: 39206747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonadherence to lipid-lowering therapy and strategies to improve adherence in patients with atherosclerotic cardiovascular disease.
    Desai NR; Farbaniec M; Karalis DG
    Clin Cardiol; 2023 Jan; 46(1):13-21. PubMed ID: 36267039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease-Real-world experience within a large integrated health care system: The IMPRES study.
    Anderson JL; Knowlton KU; May HT; Bair TL; Armstrong SO; Lappé DL; Muhlestein JB
    J Clin Lipidol; 2018; 12(4):1008-1018.e1. PubMed ID: 29703626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-lowering Therapy and Goal Achievement in High-risk Patients From French General Practice.
    Ferrières J; Gorcyca K; Iorga ŞR; Ansell D; Steen DL
    Clin Ther; 2018 Sep; 40(9):1484-1495.e22. PubMed ID: 30126705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: Five years of clinical follow-up from 164,565 post-myocardial infarction patients.
    Schiele F; Quignot N; Khachatryan A; Gusto G; Villa G; Kahangire D; Chauny JV; Ricci L; Desamericq G
    Int J Cardiol; 2021 Jun; 332():22-28. PubMed ID: 33705845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.